

George Etherington  
Health Protection Agency, UK



## Monitoring for Dose Assessment

4<sup>th</sup> EURADOS Winter School

**Radiological emergencies – Internal exposures**

Rome, 3 February 2010

# Occupational vs. emergency monitoring

|  | Normal                 | Emergency                           |                          |
|--|------------------------|-------------------------------------|--------------------------|
|  | Occupational Exposures | Accident with off-site consequences | Malevolent use incident  |
| <b>Location</b>                        | Known                  | Known                               | Unknown                  |
| <b>Site-specific plans</b>             | Yes                    | Yes                                 | No                       |
| <b>Environment</b>                     | Nuclear site           | Rural                               | Urban                    |
| <b>Numbers of people affected</b>      | Low                    | Low → Moderate                      | Low → Moderate → High    |
| <b>Response time</b>                   | Fast                   | Fast                                | ? (especially if covert) |
| <b>Level of exposure</b>               | Low                    | Low → Moderate                      | Low → Moderate → High    |
| <b>Conventional injuries to public</b> | No                     | No                                  | Possible                 |

# A lesson from Goiânia

| <b>Group</b>   | <b>Number</b>      | <b>% of population</b> |
|--|--------------------|------------------------|
| <b>Total population</b>                                    | <b>~ 1,000,000</b> | <b>100</b>             |
| <b>People monitored</b>                                    | <b>112,000</b>     | <b>11</b>              |
| <b>People with significant external and internal doses</b> | <b>249</b>         | <b>0.025</b>           |
| <b>People admitted to hospital</b>                         | <b>49</b>          | <b>0.005</b>           |
| <b>People needing intensive medical care</b>               | <b>22</b>          | <b>0.002</b>           |
| <b>Deaths</b>  | <b>4</b>           | <b>0.0004</b>          |
| <b>Severe trauma (amputation)</b>                          | <b>1</b>           | <b>0.0001</b>          |




# Objectives of individual monitoring

1. To quantify absorbed doses to organs for people who may be at risk of deterministic effects on their health (e.g. acute radiation syndrome)
  - providing an input to decisions on medical treatment
2. To quantify effective doses for people exposed at lower levels but still potentially at risk of stochastic effects on their health (cancer induction)
  - providing an input to decisions on “decorporation” (e.g. use of Prussian Blue for radiocaesium intakes)
3. To identify the potentially large numbers of people for whom exposures are unlikely to have an effect on health
  - e.g. the “worried well”

# Triage

Triage: Simple procedures for rapidly sorting people into groups for further actions

**TMT Handbook** 



| Triage Stage  |                 | Typical time period when triage decisions will be made | Information available   |
|---|-----------------|--|---|
| Trauma  |                 | 0-12 h   | Severity of physical injuries to individuals  |
| Radiological  | Pre-monitoring  | 2-36 h   | Location, etc., at time of incident   |
|   |                 | 0 h – 6 days   | Clinical signs and symptoms, and in the later stages, the results of complete blood counts  |
|   |                 | 6-72 h   | Results of initial screening measurements made at incident location   |
|   | Post monitoring | 12 h – 6 d   | Results of measurements made with transportable <i>in vivo</i> monitoring facilities close to incident location                                 |
|   |                 | 24 h – 6 d   | Results of laboratory <i>in vivo</i> monitoring measurements  |
|   |                 | 72 h – 6 d   | Results of laboratory <i>in vitro</i> measurements of biological samples (e.g. radionuclides in urine, cytogenetic measurements of blood, etc.) |
| <p>Notes.</p> <ol style="list-style-type: none"> <li>1. The results of radiological monitoring will continue to be received well beyond the end of the period where triage decisions are expected to be made. For some cases, the same will apply to the results of observations of clinical signs and symptoms.</li> <li>2. For some types of incident, not all of these triage stages would arise.</li> </ol> |                 |  |   |

# Monitoring equipment & techniques



NaI(Tl) monitor, © HPA



A simple NaI(Tl) gamma spectrometer

© STUK



Portal monitor,

© HPA



Portable radionuclide identifier, © HPA

Lap geometry  
"whole body"  
measurement

© STUK



# Monitoring equipment & techniques



© STUK


Truck-based whole body counter  
STUK, Finland

# Monitoring equipment & techniques



© IRSN

IRSN's new mobile vehicle for body counting  
IRSN, France



© IRSN

Measurement station of IRSN's  
new mobile vehicle for body  
counting

# Monitoring equipment & techniques



HPA's transportable body monitoring system

HPA, UK © HPA



# Monitoring equipment & techniques



Medical imaging system  
(gamma camera)



Laboratory whole body monitor

© HPA

# Monitoring equipment & techniques



Bioassay  
sample analysis:  
Urine monitoring

# Screening vs. measurement


Screening  
(triage)



Measurement of internal  
contamination



# Stages of monitoring



# Specifying a monitoring strategy

- Identification and characterisation of radionuclide(s)
- Identification of the people to be monitored
- Locations for individual monitoring
- Stages of monitoring
- Individual monitoring methods
- Action Levels corresponding to the various actions that should be performed after individual monitoring
- Dose Assessment
- Long term follow-up monitoring
- Recording and reporting of monitoring results

# Monitoring strategy: methods

| Radionuclide (absorption type) |                   | Radiation type emitted | Rapid screening method                     | Primary monitoring method                          |
|--------------------------------|-------------------|------------------------|--|--|
| Manganese-54 (F)               | <sup>54</sup> Mn  | γ (EC)                 | Whole body (rapid)                         | Whole body   |
| Cobalt-60                      | <sup>60</sup> Co  | β, γ                   | Whole body (rapid)                         | Lung   |
| Strontium-90                   | <sup>90</sup> Sr  | β                      | Nose blow/nasal swab                       | Urine  |
| Selenium-75                    | <sup>75</sup> Se  | γ (EC)                 | Whole body (rapid)                         | Whole body   |
| Silver-110m                    | <sup>110</sup> Ag | β, γ                   | Whole body (rapid)                         | Whole body   |
| Cadmium-109                    | <sup>109</sup> Cd | γ (EC)                 | Whole body (rapid)<br>Nose blow/nasal swab | Whole body, urine                                  |
| Iodine-131                     | <sup>131</sup> I  | β, γ                   | Thyroid (rapid)                            | Thyroid  |
| Barium-133                     | <sup>133</sup> Ba | γ (EC)                 | Whole body (rapid)                         | Whole body   |
| Caesium-137                    | <sup>137</sup> Cs | β, γ                   | Whole body (rapid)                         | Whole body   |
| Europium-152                   | <sup>152</sup> Eu | β, γ                   | Whole body (rapid)                         | Whole body   |
| Europium-154                   | <sup>154</sup> Eu | β, γ                   | Whole body (rapid)                         | Whole body   |
| Iridium-192 (F)                | <sup>192</sup> Ir | β, γ                   | Whole body (rapid)                         | Whole body   |
| Polonium-210                   | <sup>210</sup> Po | α                      | None                                       | Urine  |
| Radium-226                     | <sup>226</sup> Ra | α                      | Nose blow/nasal swab                       | Lung, Urine  |
| Plutonium-238                  | <sup>238</sup> Pu | α                      | Nose blow/nasal swab                       | Urine, Faeces <sup>1</sup><br>(Lung <sup>2</sup> ) |
| Americium-241                  | <sup>241</sup> Am | α, γ                   | Nose blow/nasal swab                       | Lung   |
| Californium-252                | <sup>252</sup> Cf | α                      | Nose blow/nasal swab                       | Urine, Faeces <sup>1</sup><br>(Lung <sup>2</sup> ) |

TMT Handbook 

# Upper Action Levels on dose


## Internal contamination

- **$E_{50} = 200 \text{ mSv}$** 
  - Level proposed by TIARA project above which medical treatment to reduce doses (e.g. by decorporation) should be considered (Menetrier et al., 2005)

## External contamination

- **$D = 2 \text{ Gy to skin}$** 
  - 20% of the level recommended by IAEA (Generic Procedures for Medical Response (IAEA-EPR-MEDICAL 2005)) for immediate decontamination, immediate medical examination, and medical treatment.

# Upper & Lower Action Levels



# Action Levels on measured quantities

## Example #1: $^{60}\text{Co}$ inhalation

TMT Handbook 

Table A10.3b. Action levels for Cobalt-60, Inhalation, Type S

| Radio-nuclide   | Action Level on:                                   | Method             | AL <sub>u</sub> |         |         |         |         | Initial value for AL <sub>u</sub> / AL <sub>l</sub> |
|-----------------|--|--------------------|-----------------|---------|---------|---------|---------|---|
|                 |  |                    | 12 h            | 1 d     | 3 d     | 7 d     | 14 d    |   |
| Co-60<br>Type S | External contamination                             | External scan      | 2,1E+05         | 1,1E+05 | -       | -       | -       | 10  |
|                 | Internal contamination - rapid initial screening   | Whole body (rapid) | 6,7E+06         | 5,0E+06 | 1,6E+06 | 8,4E+05 | 7,6E+05 | 10  |
|                 | Internal contamination - primary monitoring method | Lung               | 8,3E+05         | 8,0E+05 | 7,7E+05 | 7,4E+05 | 6,9E+05 | 10  |

### Notes

AL<sub>u</sub> - Upper Action Level

AL<sub>l</sub> - Lower Action Level

- Comparison with Action Level not valid at these times

Action levels are expressed in Bq, except for external contamination (Bq cm<sup>-2</sup>) and urinary excretion (Bq d<sup>-1</sup>)

Dose calculations were performed using the assumptions specified in Annex 13

# Action Levels on measured quantities

## Example #2: $^{210}\text{Po}$ ingestion

Table A10.14b. Action levels for Polonium-210, Ingestion

| Radio-nuclide | Action Level on:                                   | Method        | AL <sub>u</sub> |         |         |         |         | Initial value for AL <sub>u</sub> / AL <sub>l</sub> |
|---------------|--|---------------|-----------------|---------|---------|---------|---------|---|
|               |  |               | 12 h            | 1 d     | 3 d     | 7 d     | 14 d    |   |
| Po-210        | External contamination                             | External scan | 2,4E+11         | 1,2E+11 | -       | -       | -       | 10  |
|               | Internal contamination - rapid initial screening   | None          | ~               | ~       | ~       | ~       | ~       | 10  |
|               | Internal contamination - primary monitoring method | Urine         | -               | 1,6E+02 | 3,6E+02 | 3,4E+02 | 2,9E+02 | 10  |

### Notes

AL<sub>u</sub> - Upper Action Level

AL<sub>l</sub> - Lower Action Level

- Comparison with Action Level not valid at these times

Action levels are expressed in Bq, except for external contamination (Bq cm<sup>-2</sup>) and urinary excretion (Bq d<sup>-1</sup>)

Dose calculations were performed using the assumptions specified in Annex 13

# Action Levels for children

---


- **In some cases, assessed doses for children are significantly greater than for adults**
- **Action Levels for children should therefore be reduced from their adult values**
- **Reduction by a factor of 10 is appropriate**
- **Action Levels may be revised subsequently on the basis of more realistic dosimetry calculations**

# Accuracy of Action Levels

- TMT's Action Levels on measured quantities were determined using bioassay calculations that used default assumptions and model parameter values
- Relationship between measured quantity and dose is not intended to have a high level of accuracy
- Nevertheless, Action Levels should be adequate for the intended purpose, i.e.


**to facilitate decisions about further actions**

# Actions after internal contamination measurement




**TMT Handbook**

# TIARA method: $^{137}\text{Cs}$ whole body measurement



# Assessment of internal doses from monitoring data



# RBE factors for severe deterministic effects (IAEA)

*Table H4 Relative Biological Effectiveness (RBE) for severe deterministic effects*

| <b>Radiation</b>                            | <b>RBE</b> |
|---|------------|
| Gamma-radiation & X-radiation               | 1          |
| Beta particles                              | 1          |
| Alpha particles irradiating lungs           | 7          |
| Alpha particles irradiating red bone marrow | 2          |
| Alpha particles irradiating colon           | 0          |
| Iodine-131 irradiating thyroid              | 0.2        |

From Table F1, Generic procedures for medical response during a nuclear or radiological emergency. IAEA / WHO EPR-Medical 2005

# Action Levels on organ absorbed doses (IAEA)

Table H6 Generic reference levels on RBE-weighted absorbed dose <sup>1</sup>

| Organ                                       | RBE-weighted absorbed dose (Gy-Eq) <sup>2</sup> |
|---|---|
| Red marrow (intakes of actinides)           | 0.2   |
| Red marrow (intakes of other radionuclides) | 2   |
| Thyroid <sup>3</sup>                        | 2   |
| Lung  | 30  |
| Colon                                       | 20  |

Notes

1. From Table F2, Generic procedures for medical response during a nuclear or radiological emergency. IAEA / WHO EPR-Medical (2005).
2. Integration period = 30 d.
3. For use only when the thyroid is the critical organ

**If these values are exceeded, then:**

- refer immediately for medical assessment
- consider for:
  - treatment
  - decorporation therapy
  - stable iodine, as appropriate

# Dose per unit measurement “look-up” tables

Table 2c. Doses from an Intake by INGESTION of  $^{60}\text{Co}$  ( $f_1 = 0.1$ ) corresponding to a measurement of 1 Bq In WHOLE BODY at specified times after a single Intake

| Measured quantity:<br>Whole body | Intake, Bq | Organ : | RBE-weighted absorbed dose, Gy-Eq |                 |         | Effective dose, Sv |
|----------------------------------|------------|---------|-----------------------------------|-----------------|---------|--------------------|
|                                  |            |         | Lungs                             | Red bone marrow | Colon   |                    |
|                                  |            |         | 30 d                              |                 |         |                    |
| Integration period :             |            |         |                                   |                 |         |                    |
| Measurement time                 |            |         |                                   |                 |         |                    |
| 6 h                              | 1.01       |         | 2.1E-10                           | 5.8E-10         | 7.0E-09 | 3.4E-09            |
| 12 h                             | 1.09       |         | 2.2E-10                           | 6.2E-10         | 7.5E-09 | 3.7E-09            |
| 1 d                              | 1.41       |         | 2.9E-10                           | 8.0E-10         | 9.8E-09 | 4.8E-09            |
| 2 d                              | 2.89       |         | 6.0E-10                           | 1.7E-09         | 2.0E-08 | 9.8E-09            |
| 3 d                              | 6.13       |         | 1.3E-09                           | 3.5E-09         | 4.2E-08 | 2.1E-08            |
| 4 d                              | 11.5       |         | 2.4E-09                           | 6.6E-09         | 8.0E-08 | 3.9E-08            |
| 5 d                              | 17.9       |         | 3.7E-09                           | 1.0E-08         | 1.2E-07 | 6.1E-08            |
| 6 d                              | 23.3       |         | 4.8E-09                           | 1.3E-08         | 1.6E-07 | 7.9E-08            |
| 7 d                              | 27.0       |         | 5.6E-09                           | 1.5E-08         | 1.9E-07 | 9.2E-08            |
| 10 d                             | 33.4       |         | 6.9E-09                           | 1.9E-08         | 2.3E-07 | 1.1E-07            |
| 14 d                             | 39.6       |         | 8.2E-09                           | 2.3E-08         | 2.7E-07 | 1.3E-07            |
| 21 d                             | 48.3       |         | 1.0E-08                           | 2.8E-08         | 3.3E-07 | 1.6E-07            |
| 28 d                             | 54.7       |         | 1.1E-08                           | 3.1E-08         | 3.8E-07 | 1.9E-07            |

# Dose per unit measurement: Assumptions

- All calculations performed for adults
- Single (acute) intake
- Activity Median Aerodynamic Diameter (AMAD) = 5  $\mu\text{m}$
- Occupational exposure defaults for other particle size parameters
- Default physical activity levels as given in ICRP Publication 71
- Models: calculations performed using the ICRP Publication 66 Respiratory Tract Model, the current biokinetic models described in ICRP Publications 30, 56, 67 and 69, and the ICRP Publication 30 gastro-intestinal tract model.

# Limitations on use of TMT dose assessment tables

Calculations use a combination of default parameter values

- **Particle size distribution** could be highly variable
- **Absorption Type** is dependent on chemical form, on which information would be sparse
- **Intake pathway** may be uncertain
- **Measurements** (particularly rapid screening measurements) could have large uncertainties

Therefore, while dose assessments based on default values for input data may be adequate for initial dose assessments ..

... they may not be adequate as a final assessment if doses are significant

# Some other issues

---

- Time needed to initiate response
- Triage procedures
- Monitoring throughput
- Locations for monitoring, and other practical issues
- Control of exposure for workers
- Collecting information from people
- Providing information to people
- Recording and reporting individual monitoring data
- Press and public relations
- Psychological issues (public and workers)

# Selected information resources

- Radiation Event Medical Management website: <http://www.remm.nlm.gov>
- Radiation Emergency Assistance Centre (REAC/TS) website. <http://orise.orau.gov/reacts/index.htm>
- TMT Handbook website: <http://www.tmthandbook.org>
- IAEA Response Assistance Network: [http://www-pub.iaea.org/MTCD/publications/PDF/Ranet2006\\_web.pdf](http://www-pub.iaea.org/MTCD/publications/PDF/Ranet2006_web.pdf)
- IAEA Manual for First Responders to a Radiological Emergency. [http://www-pub.iaea.org/MTCD/publications/PDF/EPR\\_First\\_Responder\\_web.pdf](http://www-pub.iaea.org/MTCD/publications/PDF/EPR_First_Responder_web.pdf)
- IAEA Generic Procedures for Assessment and Response during a Radiological Emergency. [http://www-pub.iaea.org/MTCD/publications/PDF/te\\_1162\\_web.pdf](http://www-pub.iaea.org/MTCD/publications/PDF/te_1162_web.pdf)
- IAEA Generic Procedures for Medical Response during a Nuclear or Radiological Emergency. [http://www-pub.iaea.org/MTCD/publications/PDF/EPR-MEDICAL-2005\\_web.pdf](http://www-pub.iaea.org/MTCD/publications/PDF/EPR-MEDICAL-2005_web.pdf)
- Health Physics 2005; **89**(5). Several papers are of interest.

# Acknowledgements

---

TMT Handbook principal authors:

Carlos Rojas Palma, Klaas van der Meer (SCK-CEN, Belgium)

Astrid Liland, Ane Jerstad, Alicja Jaworska (NRPA Norway)

Tua Rahola, Maarit Muikku (STUK Finland)

Maria Perez, Zhanat Carr (WHO)

Karen Smith (Enviros, UK)

Genowefa Smagala (CLOR Poland)

Alan Hodgson, Mike Youngman, Peter Pellow (HPA, UK)

TMT HANDBOOK was part-funded by the European Commission (DG Research) within the 6th Framework Programme (Euratom) Contract No. FP6 - 36497

George Etherington  
Health Protection Agency, UK



## Monitoring for Dose Assessment

4<sup>th</sup> EURADOS Winter School

**Radiological emergencies – Internal exposures**

Rome, 3 February 2010